Volume 9 Supplement 2

Proceedings of the 8th International Conference on Alzheimer's Disease Drug Discovery

Reviews

Edited by Howard Fillit

The publication of this supplement was made possible by the generous support of the conference sponsors: Forest Laboratories, Inc.; Bellus Health Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Esai, Inc., Ortho-McNeil Neurologics, Inc.; Sanofi-Aventis US, Inc.; Schering-Plough; Accera, Inc.; Acumen Pharmaceuticals, Inc.; Pfizer Inc.; and Wyeth Research.

8th International Conference on Alzheimer's Disease Drug Discovery. Go to conference site.

New York, NY, USA

15-16 October 2007

  1. Review

    Small molecule activators of the Trk receptors for neuroprotection

    The neurotophin signaling network is critical to the development and survival of many neuronal populations. Especially sensitive to imbalances in the neurotrophin system, cholinergic neurons in the basal foreb...

    Nicholas JG Webster and Michael C Pirrung

    BMC Neuroscience 2008 9(Suppl 2):S1

    Published on: 3 December 2008

  2. Review

    Physiological and pathological aspects of Aβ in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators

    Many studies have highlighted the pathological involvement of iron accumulation and iron-related oxidative stress (OS) in Alzheimer's disease (AD). Iron was further demonstrated to modulate expression of the A...

    Yael Avramovich-Tirosh, Tamar Amit, Orit Bar-Am, Orly Weinreb and Moussa BH Youdim

    BMC Neuroscience 2008 9(Suppl 2):S2

    Published on: 3 December 2008

  3. Review

    Selective amyloid-β lowering agents

    The amyloid-β peptide (Aβ), implicated in the pathogenesis of Alzheimer's disease (AD), is produced through sequential proteolysis of the Aβ precursor protein (APP) by β- and γ-secretases. Thus, blocking eithe...

    Michael S Wolfe

    BMC Neuroscience 2008 9(Suppl 2):S4

    Published on: 3 December 2008

  4. Review

    Therapeutic potential of resveratrol in Alzheimer's disease

    Several epidemiological studies indicate that moderate consumption of red wine is associated with a lower incidence of dementia and Alzheimer's disease. Red wine is enriched in antioxidant polyphenols with pot...

    Valérie Vingtdeux, Ute Dreses-Werringloer, Haitian Zhao, Peter Davies and Philippe Marambaud

    BMC Neuroscience 2008 9(Suppl 2):S6

    Published on: 3 December 2008

  5. Review

    NADPH oxidase as a therapeutic target in Alzheimer's disease

    At present, available treatments for Alzheimer's disease (AD) are largely unable to halt disease progression. Microglia, the resident macrophages in the brain, are strongly implicated in the pathology and prog...

    Michelle L Block

    BMC Neuroscience 2008 9(Suppl 2):S8

    Published on: 3 December 2008

  6. Review

    Immune defects in Alzheimer's disease: new medications development

    Alzheimer's disease (AD) is a neurodegenerative disease characterized by the accumulation of intracellular and extracellular aggregates. According to the amyloid beta (Aβ) hypothesis, amyloidosis occurring in ...

    John R Cashman, Senait Ghirmai, Kenneth J Abel and Milan Fiala

    BMC Neuroscience 2008 9(Suppl 2):S13

    Published on: 3 December 2008

  7. Review

    Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase

    The peptides angiotensin IV and LVV-hemorphin 7 were found to enhance memory in a number of memory tasks and reverse the performance deficits in animals with experimentally induced memory loss. These peptides ...

    Siew Yeen Chai, Holly R Yeatman, Michael W Parker, David B Ascher, Philip E Thompson, Hayley T Mulvey and Anthony L Albiston

    BMC Neuroscience 2008 9(Suppl 2):S14

    Published on: 3 December 2008

  8. Review

    Cognitive-enhancing effects of angiotensin IV

    Angiotensin IV is a derivative of the potent vasoconstrictor angiotensin II and it has been shown to enhance acquisition, consolidation and recall in animal models of learning and memory when administered cent...

    Paul R Gard

    BMC Neuroscience 2008 9(Suppl 2):S15

    Published on: 3 December 2008

  9. Review

    Hypometabolism as a therapeutic target in Alzheimer's disease

    The pathology of Alzheimer's disease (AD) is characterized by cerebral atrophy in frontal, temporal, and parietal regions, with senile plaques, dystrophic neurites, and neurofibrillar tangles within defined ar...

    Lauren C Costantini, Linda J Barr, Janet L Vogel and Samuel T Henderson

    BMC Neuroscience 2008 9(Suppl 2):S16

    Published on: 3 December 2008